Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Melanoma Development Depends on the Activity of the RUNX2 Transcription Factor

By BiotechDaily International staff writers
Posted on 28 Apr 2014
Image: Expression of RUNX2 in the nucleus of 1205LU melanoma cells (Photo courtesy of the Rutgers Cancer Institute).
Image: Expression of RUNX2 in the nucleus of 1205LU melanoma cells (Photo courtesy of the Rutgers Cancer Institute).
The transcription factor RUNX2 (runt-related transcription factor 2) has been found to play a critical role in melanomagenesis, the processes leading to development of the skin cancer, melanoma.

The RUNX2 gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with a Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression.

Investigators at the Rutgers Cancer Institute (New Brunswick, NJ, USA) examined the role of the RUNX2 transcription factor in melanomagenesis. They reported in the March 31, 2014, online edition of the journal Cancer Letters that the expression of transcriptionally active RUNX2 was increased in melanoma cell lines as compared with normal human melanocytes. Using a melanoma tissue microarray, they showed that RUNX2 levels were higher in melanoma cells as compared with nevic melanocytes.

Genetic silencing of RUNX2 in melanoma cell lines significantly decreased Focal Adhesion Kinase expression and inhibited cell growth, migration, and invasion ability. Furthermore, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration.

“Successful efforts to render transcription factors “drugable” by interfering with different aspects of their transcriptional activity make this class of proteins attractive targets for therapy,” said senior author Dr. Karine Cohen-Solal, assistant professor of medicine at the Rutgers Cancer Institute. “Exploring the role of RUNX2 in the development of melanoma is likely to reveal new mechanisms driving melanoma progression and identify a target for novel antimelanoma agents, thereby opening new avenues for the treatment of this disease.”

Related Links:
Rutgers Cancer Institute



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.